Indication
Epithelial ovarian cancer with BRCA mutation
Epithelial ovarian cancer with a *BRCA* mutation refers to a malignant neoplasm arising from the epithelial surface of the ovary, fallopian tube, or primary peritoneum in patients harboring deleterious germline or somatic mutations in the *BRCA1* or *BRCA2* tumor suppressor genes. Read more about Epithelial ovarian cancer with BRCA mutation
6 drugs 6 manufacturers
Drugs that treat it
Common Epithelial ovarian cancer with BRCA mutation therapies.
ZEJULA (niraparib tosylate)
LYNPARZA (olaparib)
ZEJULA (niraparib tosylate)
RUBRACA (rucaparib camsylate)
RUBRACA (rucaparib camsylate)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonEpithelial ovarian cancer with a *BRCA* mutation refers to a malignant neoplasm arising from the epithelial surface of the ovary, fallopian tube, or primary peritoneum in patients harboring deleterious germline or somatic mutations in the *BRCA1* or *BRCA2* tumor suppressor genes.
This clinical biomarker subgroup most commonly presents in adult women as high-grade serous carcinoma, typically manifesting at advanced stages with peritoneal dissemination, ascites, and abdominal pelvic symptoms.
Pathophysiologically, the loss of functional BRCA protein impairs homologous recombination repair of double-strand DNA breaks, resulting in genomic instability that drives malignant transformation while simultaneously conferring increased cellular vulnerability to DNA-damaging interventions.
Consequently, this molecular subtype is clinically distinguished by heightened initial responsiveness to platinum-based chemotherapies and targeted sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors via synthetic lethality.
- nih.gov
Epithelial ovarian cancer with a *BRCA* mutation refers to a malignant neoplasm arising from the epithelial surface of the ovary, fallopian tube, or primary peritoneum in patients harboring deleterious germline or somatic mutations in the *BRCA1* or *BRCA2* tumor suppressor genes Pathophysiologically, the loss of functional BRCA protein impairs homologous recombination repair of double-strand DNA breaks, resulting in genomic instability that drives malignant transformation while simultaneously c...
- esmo.org
Epithelial ovarian cancer with a *BRCA* mutation refers to a malignant neoplasm arising from the epithelial surface of the ovary, fallopian tube, or primary peritoneum in patients harboring deleterious germline or somatic mutations in the *BRCA1* or *BRCA2* tumor suppressor genes This clinical biomarker subgroup most commonly presents in adult women as high-grade serous carcinoma, typically manifesting at advanced stages with peritoneal dissemination, ascites, and abdominal pelvic symptoms Conse...
- nih.gov
This clinical biomarker subgroup most commonly presents in adult women as high-grade serous carcinoma, typically manifesting at advanced stages with peritoneal dissemination, ascites, and abdominal pelvic symptoms
Personalize your experience
Follow Epithelial ovarian cancer with BRCA mutation and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.